...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
【24h】

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.

机译：阿托莫西汀治疗32例精神分裂症患者认知障碍的随机双盲试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Currently available antipsychotic medications offer only modest, if any, effects on cognitive performance in people with schizophrenia. Treatments that would improve these impairments could lead to better functional outcomes. Atomoxetine is a nonstimulant, selective norepinephrine reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder. In animals, it has been shown to increase extracellular levels of acetylcholine and dopamine in cortical and hippocampal regions. METHOD: Following a 2-week stabilization period, 32 subjects with DSM-IV-diagnosed schizophrenia or schizoaffective disorder were randomly assigned to atomoxetine (80 mg daily) or placebo for 8 weeks. All subjects were treated with antipsychotic monotherapy (excluding clozapine, aripiprazole, and first-generation antipsychotics). Neuropsychological test performance was the primary outcome variable, and the neuropsychological test battery included measures of attention, motor speed, executive function, processing speed, verbal and visual memory, and working memory (rated at baseline and end point). Symptom and side-effect ratings were performed every 2 weeks. The study was conducted from April 2004 through December 2006. RESULTS: There were no treatment group differences on the primary study outcome measure (overall mean z-score: Wilcoxon chi(2) = 0.21, df = 1, p = .64); nor was there significant evidence of variation in treatment effects on z-score changes across the individual neuropsychological tests (chi(2) = 8.22, df = 8, p = .41). No between-group differences were noted in symptom changes. Atomoxetine was well tolerated and was associated with a trend for improvement in extrapyramidal side effects relative to placebo (p = .063). CONCLUSION: Our results provide further evidence that atomoxetine has limited benefit for improving cognition in people with schizophrenia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00161031.
机译：背景：目前可用的抗精神病药物仅对精神分裂症患者的认知表现产生适度的影响。可以改善这些障碍的治疗方法可以改善功能。 Atomoxetine是一种非兴奋性，选择性去甲肾上腺素再摄取抑制剂，已被批准用于治疗注意力不足/多动症。在动物中，已证明可增加皮质和海马区乙酰胆碱和多巴胺的细胞外水平。方法：在2周的稳定期后，将32名经DSM-IV诊断为精神分裂症或精神分裂症的受试者随机分配至阿托西汀（每日80 mg）或安慰剂8周。所有受试者均接受抗精神病药物单药治疗（不包括氯氮平，阿立哌唑和第一代抗精神病药）。神经心理测验表现是主要的结果变量，神经心理测验表包括注意，运动速度，执行功能，处理速度，语言和视觉记忆以及工作记忆（在基线和终点评估）的量度。每两周进行一次症状和副作用评定。该研究于2004年4月至2006年12月进行。结果：主要研究结局指标上治疗组无差异（总体平均z评分：Wilcoxon chi（2）= 0.21，df = 1，p = .64）;在各个神经心理学测试中，也没有明显的证据显示治疗效果对z评分变化的变化（chi（2）= 8.22，df = 8，p = .41）。症状变化未发现组间差异。相对于安慰剂，阿托西汀具有良好的耐受性，并且与锥体束外副作用的改善趋势有关（p = .063）。结论：我们的结果提供了进一步的证据，证明阿托西汀在改善精神分裂症患者认知方面的作用有限。试验注册：clinicaltrials.gov标识符：NCT00161031。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号